The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.

Completed · Phase 2

Conditions studied: Candidiasis

In brief

Anidulafungin may be effective for the treatment of invasive Candida infections. The purpose of the study is to find the balance between dose tolerance and effectiveness of several doses for the treatment of United States patients with invasive candidiasis.

Key facts

Study ID

NCT00037219

Run by

Pfizer

People needed

120

Starts

2001-08-01

Expected to finish

2002-11-01

Last updated by the study team

2008-10-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Positive culture plus at least one clinical sign and symptom consistent with invasive candidiasis preferably within 96 hours of the proposed first dose of study drug
• Life expectancy: greater than 72 hours

You may not qualify if…

• Pregnant Females
• Treatment with other investigational drug(s) within 4 weeks
• Hypersensitivity to anidulafungin or echinocandin therapy
• Hypersensitivity to Tween 80 (polysorbate 80) or tartaric acid

Where it is running

• Versicor, Inc. — King of Prussia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.